NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lutris Pharma

Lutris Pharma

Private
Tel AvivHealthcare & Life Scienceshttps://lutris-pharma.com/

Last Round

VC Round

Jan 28, 2025

Total Funding Raised

$5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Lutris Pharma is a clinical-stage biopharmaceutical company that develops novel topical therapies to mitigate the side effects of anti-cancer treatments such as EGFR inhibitors and radiation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaltopical therapydermatological side effectsEGFR inhibitorcancer treatment adherenceB-Raf inhibitorclinical trialsskin toxicitysupportive oncologydrug developmentacneiform rashwound healingonco-dermatologyEGFRi

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lutris Pharma Comps

Public and private peers based on sector, stage, and business model.

Lutris Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Lutris Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 28, 2025
GrantOct 24, 2022
VC RoundJan 1, 2020
SeedMay 1, 2016

Key People

Founding team and executive leadership

Noa Shelach

CEO

Executive Team

Lutris Pharma Investors

Notable investors and investment history

Lutris Pharma investors
InvestorRounds
Pontifax Venture CapitalVC Round, Seed
aMoonVC Round
California Institute for Regenerative MedicineGrant
Peregrine VenturesVC Round
Columbus Venture PartnersVC Round
Arkin CapitalVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Monthly visitors increased 118% MoM.

  • Jul 7, 2025

    Presented data at the ESMO Gastrointestinal Cancers Congress 2025.

Lutris Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lutris Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lutris Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range4
Year Founded2015
Last FundingJan 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.